For cancer patient Adriana Jenkins, the term "personalized medicine" isn't just a slogan — it's the kind of treatment that helped extend her life when she was diagnosed with breast cancer in 2001. Jenkins participated in a clinical trial of Herceptin, which was then the latest drug made to combat a specific mutation driving a specific type of cancer, she writes in Forbes. "Herceptin likely extended my life by at least nine years," Jenkins says.
On Behalf of Cancer Patients
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.